Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2015

Open Access 01-12-2015 | Original investigation

Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy

Authors: Hideaki Jinnouchi, Kazunori Morita, Takahiro Tanaka, Ayami Kajiwara, Yuki Kawata, Kentaro Oniki, Junji Saruwatari, Kazuko Nakagawa, Koji Otake, Yasuhiro Ogata, Akira Yoshida, Seiji Hokimoto, Hisao Ogawa

Published in: Cardiovascular Diabetology | Issue 1/2015

Login to get access

Abstract

Background

We investigated the clinical relevance of a common variant, rs4820599, in the γ-glutamyltransferase (GGT)1 gene, associated with the serum GGT level, in Japanese type 2 diabetes mellitus (T2DM) subjects.

Methods

We conducted a retrospective longitudinal study (4.9 ± 2.5 years) including 352 T2DM patients (T2DM subjects) and a cross-sectional study including 796 health screening program participants (general subjects). A real-time TaqMan allelic discrimination assay was used to identify the genotypes. Risk factors for a high brachial-ankle pulse wave velocity (baPWV) (≥1750 cm/sec) or diabetic retinopathy (DR) were determined using a generalized estimating equations approach, receiver operating characteristic (ROC) analysis or Cox proportional hazards model, etc.

Results

The frequency of the GGT1 G allele was 20.8% in the T2DM subjects, and no associations were found between the GGT1 genotype and risk of T2DM. The mean log GGT values in the T2DM and general subjects were significantly higher among G allele carriers than non-carriers. The G allele and a low HDL-C level were identified to be risk factors for a high baPWV in the T2DM subjects [odds ratio (OR) 1.80, P = 0.008; OR 1.71, P = 0.03; respectively), and a significant interactive effect between these factors was found on the risk of a high baPWV and DR. The HDL-C level at baseline was a significant predictor of a high baPWV only in G allele carriers according to the ROC analysis. This result regarding baPWV in the T2DM subjects was replicated in the general population. Meanwhile, the GGT1 genotype was not associated with the risk of DR, although it affected the principal factors involved in the risk of DR, and a low HDL-C level was also found to be a risk factor for DR only in G allele carriers.

Conclusions

We herein describe for the first time the significant interactive effects of the GGT1 G allele and a low HDL-C level on a high baPWV and DR. These findings may encourage future clinical trials comparing the efficacy of agents increasing the HDL-C levels among the GGT1 genotypes. However, well-designed studies in larger cohorts are needed to confirm our results.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y. Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity. 2012;20(4):842–8.CrossRefPubMed Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y. Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity. 2012;20(4):842–8.CrossRefPubMed
3.
go back to reference Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99(3):163–7.CrossRefPubMed Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99(3):163–7.CrossRefPubMed
4.
go back to reference Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112(14):2130–7.CrossRefPubMed Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112(14):2130–7.CrossRefPubMed
5.
go back to reference Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57(1):31–7.CrossRefPubMed Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57(1):31–7.CrossRefPubMed
6.
go back to reference Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112(14):2078–80.CrossRefPubMed Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112(14):2078–80.CrossRefPubMed
7.
go back to reference Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011;18(3):177–81.CrossRefPubMed Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011;18(3):177–81.CrossRefPubMed
8.
go back to reference Dominici S, Paolicchi A, Lorenzini E, Maellaro E, Comporti M, Pieri L, et al. Gamma-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processes. Biofactors. 2003;17(1–4):187–98.CrossRefPubMed Dominici S, Paolicchi A, Lorenzini E, Maellaro E, Comporti M, Pieri L, et al. Gamma-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processes. Biofactors. 2003;17(1–4):187–98.CrossRefPubMed
10.
go back to reference Huseby NE. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. Clin Chim Acta. 1982;124(1):103–12.CrossRefPubMed Huseby NE. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. Clin Chim Acta. 1982;124(1):103–12.CrossRefPubMed
11.
go back to reference Artur Y, Wellman-Bednawska M, Jacquier A, Siest G. Associations between serum gamma-glutamyltransferase and apolipoproteins: relationships with hepatobiliary diseases. Clin Chem. 1984;30(8):1318–21.PubMed Artur Y, Wellman-Bednawska M, Jacquier A, Siest G. Associations between serum gamma-glutamyltransferase and apolipoproteins: relationships with hepatobiliary diseases. Clin Chem. 1984;30(8):1318–21.PubMed
12.
go back to reference Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRefPubMed Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRefPubMed
13.
go back to reference Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13(1):159.CrossRefPubMedCentralPubMed Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13(1):159.CrossRefPubMedCentralPubMed
14.
go back to reference Saely CH, Rein P, Drexel H. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692. author reply 694–695.CrossRefPubMed Saely CH, Rein P, Drexel H. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692. author reply 694–695.CrossRefPubMed
15.
go back to reference Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(6):706–14.CrossRefPubMed Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(6):706–14.CrossRefPubMed
17.
go back to reference Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.CrossRefPubMedCentralPubMed Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.CrossRefPubMedCentralPubMed
18.
go back to reference Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379.CrossRefPubMedCentralPubMed Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379.CrossRefPubMedCentralPubMed
19.
go back to reference Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52.CrossRefPubMedCentralPubMed Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52.CrossRefPubMedCentralPubMed
21.
go back to reference Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.CrossRefPubMed Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.CrossRefPubMed
22.
go back to reference Von Eckardstein A, Kardassis D. High density lipoproteins: from biological understanding to clinical exploitation. Springer International Publishing; 2015. p. 337-421. Von Eckardstein A, Kardassis D. High density lipoproteins: from biological understanding to clinical exploitation. Springer International Publishing; 2015. p. 337-421.
23.
go back to reference Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11:109.CrossRefPubMedCentralPubMed Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11:109.CrossRefPubMedCentralPubMed
24.
go back to reference Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968–75.CrossRefPubMedCentralPubMed Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968–75.CrossRefPubMedCentralPubMed
25.
go back to reference Du M, Wu M, Fu D, Yang S, Chen J, Wilson K, et al. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia. 2013;56(10):2318–28.CrossRefPubMed Du M, Wu M, Fu D, Yang S, Chen J, Wilson K, et al. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia. 2013;56(10):2318–28.CrossRefPubMed
26.
go back to reference Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem. 2002;48(9):1426–31.PubMed Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem. 2002;48(9):1426–31.PubMed
27.
go back to reference Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83(4):520–8.CrossRefPubMedCentralPubMed Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83(4):520–8.CrossRefPubMedCentralPubMed
28.
go back to reference Kim YJ, Go MJ, Hu C, Hong CB, Kim YK, Lee JY, et al. Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat Genet. 2011;43(10):990–5.CrossRefPubMed Kim YJ, Go MJ, Hu C, Hong CB, Kim YK, Lee JY, et al. Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat Genet. 2011;43(10):990–5.CrossRefPubMed
29.
go back to reference Middelberg RP, Benyamin B, de Moor MH, Warrington NM, Gordon S, Henders AK, et al. Loci affecting gamma-glutamyl transferase in adults and adolescents show age x SNP interaction and cardiometabolic disease associations. Hum Mol Genet. 2012;21(2):446–55.CrossRefPubMedCentralPubMed Middelberg RP, Benyamin B, de Moor MH, Warrington NM, Gordon S, Henders AK, et al. Loci affecting gamma-glutamyl transferase in adults and adolescents show age x SNP interaction and cardiometabolic disease associations. Hum Mol Genet. 2012;21(2):446–55.CrossRefPubMedCentralPubMed
30.
go back to reference Kawai T, Ohishi M, Onishi M, Ito N, Takeya Y, Maekawa Y, et al. Cut-off value of brachial-ankle pulse wave velocity to predict cardiovascular disease in hypertensive patients: a cohort study. J Atheroscler Thromb. 2013;20(4):391–400.CrossRefPubMed Kawai T, Ohishi M, Onishi M, Ito N, Takeya Y, Maekawa Y, et al. Cut-off value of brachial-ankle pulse wave velocity to predict cardiovascular disease in hypertensive patients: a cohort study. J Atheroscler Thromb. 2013;20(4):391–400.CrossRefPubMed
31.
go back to reference Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22(9):1141–5.CrossRefPubMed Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22(9):1141–5.CrossRefPubMed
33.
go back to reference Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42(3):210–5.CrossRefPubMed Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42(3):210–5.CrossRefPubMed
34.
go back to reference Ogawa O, Hiraoka K, Watanabe T, Kinoshita J, Kawasumi M, Yoshii H, et al. Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse waveform. Cardiovasc Diabetol. 2008;7:11.CrossRefPubMedCentralPubMed Ogawa O, Hiraoka K, Watanabe T, Kinoshita J, Kawasumi M, Yoshii H, et al. Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse waveform. Cardiovasc Diabetol. 2008;7:11.CrossRefPubMedCentralPubMed
35.
go back to reference Kweon SS, Shin MH, Nam HS, Jeong SK, Park KS, Choi JS, et al. Dose–response relationship between serum gamma-glutamyltransferase and arterial stiffness in Korean adults: the Namwon Study. J Epidemiol. 2014;24(1):7–14.CrossRefPubMedCentralPubMed Kweon SS, Shin MH, Nam HS, Jeong SK, Park KS, Choi JS, et al. Dose–response relationship between serum gamma-glutamyltransferase and arterial stiffness in Korean adults: the Namwon Study. J Epidemiol. 2014;24(1):7–14.CrossRefPubMedCentralPubMed
36.
go back to reference Lin Y, Xu Y, Chen G, Huang B, Yao J, Chen Z, et al. Serum gamma-glutamyltransferase and associated damage among a She Chinese population. Diabet Med. 2011;28(8):924–31.CrossRefPubMed Lin Y, Xu Y, Chen G, Huang B, Yao J, Chen Z, et al. Serum gamma-glutamyltransferase and associated damage among a She Chinese population. Diabet Med. 2011;28(8):924–31.CrossRefPubMed
37.
go back to reference Lee DH, Jacobs Jr DR, Gross M, Steffes M. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51(7):1185–91.CrossRefPubMed Lee DH, Jacobs Jr DR, Gross M, Steffes M. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51(7):1185–91.CrossRefPubMed
38.
go back to reference Agabiti-Rosei E. From macro- to microcirculation: benefits in hypertension and diabetes. J Hypertens Suppl. 2008;26(3):S15–9.CrossRefPubMed Agabiti-Rosei E. From macro- to microcirculation: benefits in hypertension and diabetes. J Hypertens Suppl. 2008;26(3):S15–9.CrossRefPubMed
40.
go back to reference Bradley RD, Fitzpatrick AL, Jacobs Jr DR, Lee DH, Swords Jenny N, Herrington D. Associations between gamma-glutamyltransferase (GGT) and biomarkers of atherosclerosis: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2014;233(2):387–93.CrossRefPubMedCentralPubMed Bradley RD, Fitzpatrick AL, Jacobs Jr DR, Lee DH, Swords Jenny N, Herrington D. Associations between gamma-glutamyltransferase (GGT) and biomarkers of atherosclerosis: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2014;233(2):387–93.CrossRefPubMedCentralPubMed
41.
go back to reference Paolicchi A, Emdin M, Passino C, Lorenzini E, Titta F, Marchi S, et al. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186(1):80–5.CrossRefPubMed Paolicchi A, Emdin M, Passino C, Lorenzini E, Titta F, Marchi S, et al. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186(1):80–5.CrossRefPubMed
42.
go back to reference Zhao WW, Yang YH, Lu B, Feng XC, He M, Yang ZH, et al. Serum high-density lipoprotein cholesterol and progression to arterial stiffness in middle-aged and elderly Chinese. Nutr Metab Cardiovasc Dis. 2013;23(10):973–9.CrossRefPubMed Zhao WW, Yang YH, Lu B, Feng XC, He M, Yang ZH, et al. Serum high-density lipoprotein cholesterol and progression to arterial stiffness in middle-aged and elderly Chinese. Nutr Metab Cardiovasc Dis. 2013;23(10):973–9.CrossRefPubMed
43.
go back to reference Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation. 2011;124(19):2056–64.CrossRefPubMed Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation. 2011;124(19):2056–64.CrossRefPubMed
47.
go back to reference Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis. 2011;218(1):13–8.CrossRefPubMed Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis. 2011;218(1):13–8.CrossRefPubMed
49.
go back to reference Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid Med Cell Longev. 2014;2014:752387.CrossRefPubMedCentralPubMed Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. Oxid Med Cell Longev. 2014;2014:752387.CrossRefPubMedCentralPubMed
50.
go back to reference Morita K, Saruwatari J, Miyagawa H, Uchiyashiki Y, Oniki K, Sakata M, et al. Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:132.CrossRefPubMedCentralPubMed Morita K, Saruwatari J, Miyagawa H, Uchiyashiki Y, Oniki K, Sakata M, et al. Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:132.CrossRefPubMedCentralPubMed
51.
go back to reference Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5.CrossRefPubMed Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200–5.CrossRefPubMed
Metadata
Title
Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy
Authors
Hideaki Jinnouchi
Kazunori Morita
Takahiro Tanaka
Ayami Kajiwara
Yuki Kawata
Kentaro Oniki
Junji Saruwatari
Kazuko Nakagawa
Koji Otake
Yasuhiro Ogata
Akira Yoshida
Seiji Hokimoto
Hisao Ogawa
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2015
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-015-0212-5

Other articles of this Issue 1/2015

Cardiovascular Diabetology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine